Bank of America Corp DE decreased its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 27.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 75,799 shares of the company's stock after selling 28,855 shares during the period. Bank of America Corp DE owned approximately 0.26% of Krystal Biotech worth $11,875,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in KRYS. Covestor Ltd lifted its holdings in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after acquiring an additional 642 shares in the last quarter. KBC Group NV lifted its holdings in shares of Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after purchasing an additional 297 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. US Bancorp DE grew its position in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares during the period. Finally, Certuity LLC bought a new stake in Krystal Biotech during the 4th quarter worth approximately $214,000. Institutional investors own 86.29% of the company's stock.
Krystal Biotech Stock Performance
KRYS traded up $2.15 on Tuesday, hitting $127.20. 117,993 shares of the company were exchanged, compared to its average volume of 307,394. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $219.34. The company has a market cap of $3.68 billion, a PE ratio of 42.41 and a beta of 0.79. The stock's fifty day moving average is $160.06 and its 200-day moving average is $166.27.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the stock. Citigroup reduced their price target on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a report on Friday, May 16th. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. Guggenheim cut their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Krystal Biotech presently has an average rating of "Buy" and an average price target of $211.13.
Read Our Latest Report on Krystal Biotech
Insider Buying and Selling
In other news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. This trade represents a 5.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
